Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Shares Rise 11 Percent Following European OK for HPV Test

NEW YORK (GenomeWeb News) – Shares of Third Wave Technologies rose nearly 11 percent yesterday after the firm said that European regulatory authorities granted the CE Mark for the firm’s molecular diagnostic test for human papillomavirus.
 
The clearance from the European Union gives the company the green light to sell the test, which detects 14 high-risk types of HPV and is used in screening for cervical cancer, in EU member nations and in other nations that recognize the CE mark.
 
The company said it expects to market the test in Europe in January 2008.
 
Third Wave’s test will join several other molecular diagnostic tests for HPV on the European market, including assays sold by Qiagen, Roche, Biotools, and bioMérieux. Qiagen is the only firm to have both European and US clearance to sell its HPV molecular diagnostic test.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.